DalsnaFinance

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

Markets PR Newswire By PR Newswire 15 Jul 2026 11:00 1 min read
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

Mississauga, ON, July 15, 2026 /PRNewswire/ - Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare sector, is proud to announce the successful acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb, Canada as of June 29th, 2026. This strategic acquisition...

Mississauga, ON, July 15, 2026 /PRNewswire/ - Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare sector, is proud to announce the successful acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb, Canada as of June 29th, 2026. This strategic acquisition...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.